Metrics
19 Record Views
- Title
- Poster: MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
- Creators
- Sangeetha Venugopal - The University of Texas MD Anderson Cancer CenterCourtney D. DiNardo - The University of Texas MD Anderson Cancer CenterKoichi Takahashi - The University of Texas MD Anderson Cancer CenterMarina Konopleva - The University of Texas MD Anderson Cancer CenterSanam Loghavi - The University of Texas MD Anderson Cancer CenterGautam Borthakur - The University of Texas MD Anderson Cancer CenterAmy DeZern - Johns Hopkins MedicineLucia Masarova - The University of Texas MD Anderson Cancer CenterNaval Daver - The University of Texas MD Anderson Cancer CenterNicholas J. Short - The University of Texas MD Anderson Cancer CenterYesid Alvarado - The University of Texas MD Anderson Cancer CenterFarhad Ravandi - The University of Texas MD Anderson Cancer CenterGuillermo Montalban-Bravo - The University of Texas MD Anderson Cancer CenterKoji Sasaki - The University of Texas MD Anderson Cancer CenterRicardo Delumpa - The University of Texas MD Anderson Cancer CenterMikkael A. Sekeres - Sylvester Comprehensive Cancer CenterBhumika Patel - Cleveland ClinicGail J. Roboz - Cornell UniversityHagop M. Kantarjian - The University of Texas MD Anderson Cancer CenterGuillermo Garcia-Manero - The University of Texas MD Anderson Cancer Center
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.21, pp.S226-S226
- Publisher
- Elsevier Inc
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Conference poster
- Record Identifier
- 991031757857402976